


## Product Data Sheet

### Psora 4

<b>Cat. No.:</b>	B7659
<b>CAS No.:</b>	724709-68-6
<b>Formula:</b>	C <sub>21</sub> H <sub>18</sub> O <sub>4</sub>
<b>M.Wt:</b>	334.37
<b>Synonyms:</b>	
<b>Target:</b>	Membrane Transporter/Ion Channel
<b>Pathway:</b>	Potassium Channel
<b>Storage:</b>	Store at -20°C



### Solvent & Solubility

insoluble in H<sub>2</sub>O;  $\geq 1.72$  mg/mL in EtOH with ultrasonic;  $\geq 15.75$  mg/mL in DMSO

In Vitro

Preparing Stock Solutions	Solvent	Mass		
		1mg	5mg	10mg
	<b>Concentration</b>			
	<b>1 mM</b>	2.9907 mL	14.9535 mL	29.9070 mL
	<b>5 mM</b>	0.5981 mL	2.9907 mL	5.9814 mL
	<b>10 mM</b>	0.2991 mL	1.4953 mL	2.9907 mL

Please refer to the solubility information to select the appropriate solvent.

### Biological Activity

Shortsummary

Kv1.3 blocker

IC<sub>50</sub> & Target

In Vitro

#### Cell Viability Assay

Cell Line:	human and rat TEM cells
Preparation method:	The solubility of this compound in DMSO is >15.75mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37°C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.
Reacting conditions:	0-1000 nM; 30 min

	Applications:	Psora-4 preferentially inhibited the proliferation of human and rat TEM cells with EC50 values of 25 and 60 nM, respectively.
In Vivo	<b>Animal experiment</b>	
	Animal models:	rats with anti-glomerular basement membrane glomerulonephritis (anti-GBM GN)
	Dosage form:	0.3 ml; dissolved in a mixture of 25% CremophorEL and 75% PBS to prepare a concentration of 9 mg/ml; from day 0 to day 21; intraperitoneal injection
	Applications:	In rats with anti-glomerular basement membrane glomerulonephritis (anti-GBM GN), Psora 4 significantly reduced urinary protein excretion and the increase in kidney weight was significantly smaller than that in the vehicle group. Psora 4 restored creatinine clearances and reduced the proportion of crescentic glomeruli, and the number of ED-1+ macrophages and CD3+ T cells.
	Other notes:	Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal.

## Product Citations

1. Admasu TD, Chaithanya Batchu K, et al. "Drug Synergy Slows Aging and Improves Healthspan through IGF and SREBP Lipid Signaling." Dev Cell. 2018 Oct 8;47(1):67-79.e5.PMID:30269951

See more customer validations on [www.apexbt.com](http://www.apexbt.com).

## References

[1] Vennekamp J,Wulff H,Beeton C,Calabresi PA,Grissmer S,Hnsel W,Chandy KG. Kv1.3-blocking 5-phenylalkoxy-psoralens: a new class of immunomodulators. Mol Pharmacol.2004 Jun;65(6):1364-74.

[2]. Hyodo T1, Oda T, Kikuchi Y, et al. Voltage-gated potassium channel Kv1.3 blocker as a potential treatment for rat anti-glomerular basement membrane glomerulonephritis. Am J Physiol Renal Physiol. 2010 Dec;299(6):F1258-69.

## Caution

**FOR RESEARCH PURPOSES ONLY.**

**NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.**

Specific storage and handling information for each product is indicated on the product datasheet. Most APEX BIO products are stable under the recommended conditions. Products are sometimes shipped at a temperature that differs from the recommended storage temperature. Short-term storage of many products are stable in the short-term at temperatures that differ from that required for long-term storage. We ensure that the product is shipped under conditions that will maintain the quality of the reagents. Upon receipt of the product, follow the storage recommendations on the product data sheet.

---

**APEx BIO Technology**

[www.apexbt.com](http://www.apexbt.com)

7505 Fannin street, Suite 410, Houston, TX 77054.  
Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

